Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Franzese

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 19, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung CancerRichard C Franzese, Li Qin, Shuai Fu, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-MakingHerbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug DevelopmentSebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.
Clinical Pharmacology and Therapeutics|October 23, 2021
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and OlderRichard C Franzese, Lynn McFadyen, Kenny J Watson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|February 19, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung CancerRichard C Franzese, Li Qin, Shuai Fu, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-MakingHerbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug DevelopmentSebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.
Clinical Pharmacology and Therapeutics|October 23, 2021
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and OlderRichard C Franzese, Lynn McFadyen, Kenny J Watson, et al.
Pageof 1